Company
Company Overview
Ricoh Biosciences, K.K. is a wholly-owned subsidiary of Ricoh Biosciences, Inc. headquartered in Baltimore, Maryland, USA, with its base located in the Shonan Health Innovation Park in Fujisawa, Kanagawa Prefecture.
| Company Name | Ricoh Biosciences, K.K. |
| CEO | Daisuke Takagi |
| Location | Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan |
History
Established Elixirgen Scientific, Inc. Japan Branch in Yokohama, Kanagawa.
Relocated the Japan Branch to the Life Innovation Center in Kawasaki.
Expanded into Shonan Health Innovation Park in Fujisawa and launched mRNA CDMO services.
Incorporated as Elixirgen Scientific Japan, Inc.
Acquisition of additional shares in a consolidated subsidiary by Ricoh Company, Ltd. and conversion of the subsidiary into a wholly owned subsidiary.
Business Overview
- ）mRNA Contract Development & Manufacturing (CDMO) Services
- ）iPS Cell Differentiation Service
Philosophy
Through mRNA and iPSC related technologies, we contribute to human health and welfare.
Our mission is to leverage cutting-edge biotechnology to support the development of innovative pharmaceuticals and medical technologies, thereby improving health and welfare worldwide. We engage sincerely with our clients’ needs and strive to be a trusted partner by delivering high-quality products and services.
Our Strengths
- Domestic cGMP-compliant mRNA manufacturing facility in Japan
- Extensive experience and track record
- Technical expertise that ensures high-quality products
- Flexible response to customer needs
Leadership
Daisuke Takagi
President
Joined Applied Materials Japan, where he was responsible for the development of copper wiring formation processes and equipment development at both the company and Ebara Corporation. He also served as the joint research coordinator in Dresden, Germany.
Subsequently, as a new business development manager at a venture company, he experienced the listing on the Tokyo Stock Exchange Mothers market. Joined Ricoh Co., Ltd., where he launched a new material development project for printers, and in 2013, launched a bio-3D printing project and participated in an AMED project.
Joined Elixagen Scientific Co., Ltd. in 2019, and launched the CDMO business in February 2021, contributing to the expansion of the CDMO business by supporting customers from the early stages of drug discovery projects.
Appointed President and CEO in October 2024.
